Loading…
LTRN
Lantern Pharma Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 51654W101
$2.07-4.17%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $26.46M
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.63
- ROE
- -400.92%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 2.33
- 52-week high
- $4.70
- 52-week low
- $1.11
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -88.1% over 5Y.
today you would have $109.12▼ -89.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $3.03 | $3.19 | $4.28 | $6.04 | $7.98 | $19.25 | |
| P/B | 1.4x | 5.2x | 1.6x | 1.1x | 1.2x | 1.2x | 10.9x |
| EPS | -$1.57 | -$1.93 | -$1.47 | -$1.31 | -$1.13 | -$1.37 | |
| ROE | -34.51% | -262.00% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BEATHeartBeam, Inc. | $0.47 | — | 3.2x | — | -328.44% | $26.31M |
| FEMYFemasys Inc | $3.20 | — | 2.4x | — | -424.97% | $26.8M |
| ARAYAccuray Inc | $0.23 | — | 0.6x | — | -80.08% | $26.93M |
| ATOSAtossa Therapeutics Inc | $2.58 |
About the company
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
- 16
- Dallas, United States
Company description provided by Yahoo Finance.